1. Home
  2. IART vs ANL Comparison

IART vs ANL Comparison

Compare IART & ANL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Integra LifeSciences Holdings Corporation

IART

Integra LifeSciences Holdings Corporation

HOLD

Current Price

$10.04

Market Cap

823.8M

Sector

Health Care

ML Signal

HOLD

Logo Adlai Nortye Ltd.

ANL

Adlai Nortye Ltd.

HOLD

Current Price

$13.94

Market Cap

703.3M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
IART
ANL
Founded
1989
2004
Country
United States
Cayman Islands
Employees
N/A
N/A
Industry
Medical/Dental Instruments
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
823.8M
703.3M
IPO Year
1996
2022

Fundamental Metrics

Financial Performance
Metric
IART
ANL
Price
$10.04
$13.94
Analyst Decision
Hold
Strong Buy
Analyst Count
7
1
Target Price
$14.33
$20.00
AVG Volume (30 Days)
689.1K
693.8K
Earning Date
05-05-2026
04-10-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$4.39
$36.02
Revenue Next Year
$3.40
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$8.70
$0.88
52 Week High
$17.04
$17.25

Technical Indicators

Market Signals
Indicator
IART
ANL
Relative Strength Index (RSI) 47.18 56.05
Support Level $8.79 $1.36
Resistance Level $11.57 $17.25
Average True Range (ATR) 0.56 2.58
MACD -0.01 -0.24
Stochastic Oscillator 22.19 65.07

Price Performance

Historical Comparison
IART
ANL

About IART Integra LifeSciences Holdings Corporation

Integra Lifesciences Holdings Corp is a New Jersey-based medical equipment company focused on developing products for regenerative therapy, extremity orthopedics, and neurosurgical applications. The firm is organized into two primary segments: Codman specialty surgical and Tissue technologies. Codman Specialty Surgical generates maximum revenue from its segmental operations. Integra serves Europe, Asia Pacific, and the rest of the world whilst it derives key revenue from domestic sales. The company operates in United States, Europe, Asia Pacific, and Rest of the World.

About ANL Adlai Nortye Ltd.

Adlai Nortye Ltd is a clinical-stage biotechnology company focused on the discovery and development of cancer therapies for patients across the spectrum of tumor types. The company has a robust pipeline of drug candidates which includes buparlisib (AN2025), palupiprant (AN0025), and AN4005 in the clinical stage, and AN8025, AN9025, and AN1025 in the preclinical stage.

Share on Social Networks: